HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinibY. Wang, Fred R. Hirsch, Paul A. Bunn et al.|Annals of Oncology|2018Cited by 217
Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapyMegan M. Tu, Dan Theodorescu, Beth A. Jirón Tamburini et al.|Communications Biology|2020Cited by 170
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapyMegan M. Tu, Dan Theodorescu, Krista Menard et al.|Science Advances|2019Cited by 126